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Purpose: Hematologic toxicity (HT) during chemoradiation therapy (CRT) for anal cancer can lead
to treatment breaks that compromise efficacy. We hypothesized that CRT-induced HT correlates
with changes in active bone marrow (ABM) characterized by pre-/post-CRT positron emission
tomography (PET)/computed tomography.
Methods and materials: Data from 36 patients with anal cancer who were treated with 18F-
fluorodeoxyglucose PET/computed tomography scans 2 weeks before and 6 to 16 weeks after CRT
were analyzed. Complete blood counts with differential within 2 weeks from, weekly during, and
2 week after treatment were obtained. HT was defined as baseline complete blood count change to
nadir and posttreatment recovery. Total bone marrow was segmented into 2 subregions: lumbo-
sacral (LS) pelvis (L5 vertebrae, sacrum, and coccyx) and lower pelvis (LP) (ilium, femoral head/
neck, and greater and lesser trochanter). PET ABM was characterized as the volume having
standard uptake value (SUV) greater than the mean uptake of unirradiated extrapelvic bone
marrow. PET variables of pre-/post-CRT and HT predictors were analyzed by linear regression.
Results: Average pelvic ABM was significantly reduced from 52% to 41% in pre- to post-CRT
PET scans for all patients (PZ .0012). Regional analysis indicated significant post-CRT reduction
of LS-ABM (P < .0001) and LP-ABM (PZ .006). Linear regression analysis identified post-CRT
SUVmean, differential DSUVmean, and DABM as correlating significantly with pre- and
posttreatment HT. DWBC linearly correlated with DABM of LS and LP pelvis (P Z .033 and
P Z .028, respectively). Dosimetrically, ABM was sensitive to higher radiation doses (>50 Gy)
in terms of acute hematologic DWBC (P Z .021) and DANC(P Z .028). HT increased with
increasing volume of ABM receiving 40 Gy. The results also suggest that ABM
V40 Gy  20% to 25% may significantly reduce the risk of HT.Sources of support: This work had no specific funding.
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614 J.M. David et al Advances in Radiation Oncology: OctobereDecember 2019Conclusions: HT was significantly associated with DABM in patients with anal cancer who were
treated with CRT. LS-ABM was a robust surrogate for evaluating CRT-induced HT. Our results
suggest implementation of ABM dosimetric constraints, V40 Gy  20-25%, may significantly
reduce HT and lead to decreased treatment delays associated with clinical outcomes.
 2019 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation
Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Anal cancer comprises approximately 2.5% of
gastrointestinal malignancies, with an increasing inci-
dence over the last 30 years.1 Despite this, treatment with
standard-of-care chemoradiation therapy (CRT) results in
excellent rates of long-term disease-free survival and
sphincter preservation.2 However, associated treatment-
related side effects, such as hematologic toxicity (HT),
can be significant.
Improvements in radiation therapy (RT) delivery
techniques, such as intensity modulated RT (IMRT), have
led to fewer gastrointestinal toxicities and HTs compared
with 3-dimensional conformal radiation therapy.3 IMRT
allows a more conformal dose distribution to spare critical
normal tissues, such as the pelvic bones and bone
marrow. IMRT, compared with 3-dimensional conformal
RT, has resulted in reduced grade 2 and 3 HT from 85%
to 73% and 36% to 21%, respectively.3,4 Treatment in-
terruptions were also reduced, with the median duration of
treatment decreasing from 49 days to 43 days.
Unplanned treatment breaks have been correlated with
compromised oncologic efficacy owing to accelerated
repopulation.5 Increasing treatment breaks have also
resulted in worse quality of life with increased 2-year
colostomy rates.4,6 Similarly, reducing systemic chemo-
therapy, particularly mitomycin-C (MMC), reduces HT to
a greater degree than improvements in RT techniques.7
Therefore, European centers have begun using single-
dose MMC,8 and investigators have attempted to eluci-
date dosimetric IMRT constraints to reduce HT. Although
dosimetric parameters and IMRT have been helpful in
sparing the pelvic bone marrow, functional imaging such
as 18F-fluorodeoxyglucose (18F-FDG) positron emission
tomography (PET) imaging has been used to better
characterize the heterogeneity of active bone marrow
(ABM) stores in the pelvic bones.9-12 ABM stores are
detected on functional imaging by identifying areas of
increased standard uptake value (SUV). Hypermetabolic
bone marrow is thought to have increased rates of mito-
ses, requiring increased utilization of 18-flourine-tagged
glucose, thus representing dominant areas of white and
red blood cell production. Although reduction in the
whole pelvis dose has been helpful, selectively reducing
the dose to areas based on PET parameters can furtherprevent HT.13 Currently, PET scans are used in
conjunction with standard-of-care computed tomography
(CT) imaging for the initial and posttreatment staging of
patients with locally advanced anal cancer.
The objectives of this study were to characterize
bone marrow regions within pelvic bone marrow using
PET, investigate changes in ABM before and after CRT
in patients with anal cancer, and correlate these changes
with HT. We hypothesized that the ABM compartment
of the pelvic bones was accurately represented by an
increased SUV on PET, that treatment-related changes
in ABM using PET were highly associated with HT and
clinical outcomes, and that the resulting dose to ABM




We retrospectively identified treatment-naïve patients
with localized nonmetastatic squamous cell cancer of the
anus who were treated definitively with concurrent 5-
flurouracil (5-FU), MMC, and RT between 2011 and
2016. Patient data were collected independently under
institutional review boardeapproved protocols from 2
institutions. Patients with baseline pre- and post-CRT
(range, -6 to 16 weeks; median, 12 weeks; interquartile
range, 10-12.5 weeks) 18F-FDG PET/CT scans were
included in the study. The same 18F-FDG PET/CT im-
aging protocol was used at both institutions. Patients
fasted 6 hours before intravenous administration of 200 to
400 MBq of 18F-FDG 60 minutes before being scanned.
The images were collected and analyzed using the same
procedures. White blood cell (WBC) counts, absolute
neutrophil count (ANC), lymphocytes (LC), platelets
(PLT), and hemoglobin (Hg) were assessed within
8 weeks of beginning treatment, weekly during treatment,
and 2 weeks after treatment.
Chemoradiation technique
Treatment-naïve patients were treated with definitive
concurrent CRT. Chemotherapy included 5-FU (1000 mg/
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days 1 and 29). RT doses were 50.4 to 59.4 Gy in 28 to 33
fractions (55.8  2.23 Gy). Target volumes and normal
critical organs were contoured by 2 board-certified radi-
ation oncologists using the Radiation Therapy Oncology
Group (RTOG) contouring guidelines.14 Primary tumor
and clinically involved nodes were identified as gross
tumor volume and expanded to clinical target and plan-
ning target volumes using expansions of 2.5 cm and 0.7 to
1 cm, respectively. Whole pelvic and inguinal nodal ba-
sins were treated to 45 Gy in 25 fractions. Clinically
involved lymph nodes and primary tumors were treated
with additional boost doses (5.4-14.4 Gy). In addition to
other normal tissue constraints, bone marrow related
constraints were specially considered: V50 Gy < 5%,
V40 Gy < 35%, and V30 Gy < 50%. All patients were
treated with static fieldeor volumetric arcebased IMRT.Pelvic contours and segmentation
Whole-body CT scans obtained as part of PET/CT
were used to segment the bone marrow. The whole pelvic
bone marrow was outlined following outer contours using
a bone window. Total bone marrow (TBM) of the pelvis,
including bilateral L5 vertebral body, sacrum, coccyx,
ilium, femoral heads, femoral necks, and greater and
lesser trochanters, was contoured. Two subregions of
pelvic TBM were identified, as shown in Figure 1: (a)
lumbosacral bone marrow (LSBM), comprising the L5
vertebral body, entire sacrum, and coccyx; and (b) the
remainder of the pelvis, referred to as the lower part of the
pelvis (LPBM) and comprising the femoral head, femoral
neck, greater trochanter, and lesser trochanter. The
extrapelvic bone marrow was also contoured, including
the C4-L4 vertebrae, scapulae/proximal humeri, clavicles/
sternum, and ribs.
The aforementioned subregion segmentation is built
upon the results of our preliminary study on 21 patients,15
where the pelvis bone was divided into 3 subregions: iliac
bone (ilium, iliac crest), lower pelvis (pubic, ischium,Figure 1 (a) Pelvic total bone marrow with 2 subregions identified:
Pre-CRT PET-defined active bone marrow (orange). (c) Post-CRT act
therapy; PET Z positron emission tomography.femoral head, and femoral neck), and lumbosacrum. We
found that the metabolic uptake of the iliac and lower
pelvic bones was similar (P Z .589) yet significantly
different from the lumbosacral regions (P Z .034 and
.011, respectively). To simplify the analysis in this study,
we integrated the lower pelvic and iliac regions into
lower-pelvis iliac regions as described.
Metabolic activity of the pelvic bone
The bone marrow metabolic activity represented by
SUV of PET images was fused on the CT images. The
average uptake of the pelvic regions, SUVmean, was
measured in the whole pelvic bone marrow, as well as
LSBM and LPBM. To reduce intrapatient image varia-
tions, pelvic SUVmean was normalized by subtracting the
mean uptake of unirradiated extrapelvic bone marrow.
Changes in metabolic activity before and after CRT were
calculated as DSUVmean Z SUVmean_post-CRTeSUV-
mean_pre-CRT and correlated with treatment response.
Active bone marrow
Pelvic ABM was characterized in all PET images as
the volume having an SUV greater than the threshold,
where the threshold is defined as the mean uptake in the
extrapelvic bone marrow. Subregional ABM was also
measured for LSBM and LPBM, referred to LS-ABM and
LP-ABM, respectively. We calculated ABM volumes and
determined the proportion of ABM within each structure:
ABM ratio Z Volume of ABM/Volume of BM. The
ABM volumes and their ratios to bone marrow volume
were calculated before and after CRT, respectively. The
CRT-induced ABM changes were calculated as the
changes of ABM ratio between pre- and post-CRT, such
as DABM Z ABMpost-CRT/BMpost-CRTeABMpre-CRT/
BMpre-CRT. Correspondingly, DLS-ABM and DLP-ABM
represent the change of ABM ratio between pre- and post-
CRT in the lumbosacral and iliac-pubic regions,
respectively.lumbosacral region (yellow) and lower pelvic region (cyan). (b)
ive bone marrow (pink). Abbreviations: CRTZ chemoradiation
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Radiation dose was defined as the cumulative dose to
bone marrow during the course of RT treatment. We used
dose-volume histograms to generate multiple dose-
volume point metrics at dose levels of 10, 20, 30, 40,
and 50 Gy. This analysis was performed on multiple
volumes, including pelvic TBM, LSBM, LPBM, ABM,
and individual structure LS-ABM and LP-ABM.Hematologic toxicity and blood cell count nadirs
All patients were monitored weekly during and after
CRT for acute toxicities, including but not limited to fa-
tigue, erythema, bloating, urinary urgency, urinary fre-
quency, fecal incontinence, bleeding, dermatitis, nausea,
vomiting, constipation, diarrhea, and proctitis. HT was
graded using Common Terminology Criteria for Adverse
Events, version 4.
Acute HT is represented by the difference in blood cell
counts between nadir and baseline: Acute HT Z Cell
counts at nadireCell counts before CRT, where cell
counts can be WBC, ANC, PLT, LC, and Hg. We also
used the post-CRT HT as an alternative endpoint, where
posttreatment HT Z Cell counts after CRTeCell counts
before CRT.Statistical analysis
An independent-sample t test was used to analyze
baseline differences in age, clinical stages, and Karnof-
sky Performance Scale scores among patients from both
institutions. The Fisher exact test was used to compare
categorical variables. We used the ShapiroeWilk statistic
to test for normality of variables. The primary image-
based response was defined as the change of ratio of
the ABM% from before to after treatment. Generalized
linear modeling was used to investigate the eventual
correlation between dosimetric variables and blood cells
nadirs.
Posttreatment HT was used as the clinical endpoint for
evaluating the dosimetric results. Significant covariates
on univariable linear regression analysis were included in
the multivariable linear regression model. The Pearson
coefficient and multicollinearities index variance inflation
factor were used to evaluate the effectiveness of input
data in the multivariable analysis. The standard error of
the fit and Hosmer-Lemeshow (HL) test were used to
evaluate the goodness of model fit. The threshold of
dosimetric parameter was validated by area under the
curve of the receiver operating characteristic analysis.
MATLAB Statistical Toolbox Software (version 11.1)
and GraphPad Prism (version 7) were used for the
analysis.Results
Patients
Of the 36 patients, 18 were male (Table 1). Median age
at diagnosis was 61.5 years (range, 39-78 years). Mean
IMRT dose was 54.8  2.9 Gy. The clinical stage and
Karnofsky Performance Scale scores of before and after
CRT are shown in Table 1. The t test results indicate there
was no significant difference between the patient cohorts
of both institutions.
Pelvic total bone marrow
After segmentation of both the pre and post-CRT
pelvic TBM, the mean volumes of pre- and post-CRT
TBM were 1230  159 mm3 and 1289  168 mm3,
respectively. Figure 1 shows the TBM defined before
CRT (Fig 1b) and after CRT (Fig 1c). The results of the
pairwise t test show no significant difference between
TBM as a function of CRT (P Z .234).
Differences of pelvis metabolic activity before
and after chemoradiation therapy
The change in metabolic activity because of CRT
treatment was compared with respect to SUVmean for
TBM, LSBM, and LPBM (Fig 2). Patients’ post-CRT
SUVmean was significantly lower than that before CRT,
and the SUVmean of the LSBM (P < .0001) decreased
more significantly than that of the LPBM (P Z .011).
Difference of pelvic active bone marrow before
and after chemoradiation therapy
The ABM was segmented using the SUV of bone
marrow, which was higher than the mean SUV of the
extrapelvic bone marrow. We compared the difference
between normalized ABM before and after CRT treat-
ment (Fig 1b, 1c). The ABM in the whole pelvic region
was significantly reduced from 50% before CRT to 40%
after CRT (PZ .0012; Fig EB, available online at https://
doi.org/10.1016/j.adro.2019.06.005). Regional analysis
also indicated that the lumbosacral ABM was more
significantly (P < .0001) reduced than the LP pelvis re-
gion (P Z .006).
Acute and posttreatment hematologic toxicity
Different cell types reached their nadir at different time
points: week 5 or 6 for WBC, ANC, Hg, and LC versus
the week 3 for PLT nadir (Fig EC; available online at
https://doi.org/10.1016/j.adro.2019.06.005). Consistently
across all cell types, the greatest reduction toward nadir
Table 1 Patient characteristics
Variables (N Z 36) All (36 pts) Institution I (21 pts) Institution II (15 pts) P-value
Age, median (range), y 61.5 (39-78) 62 (39-78) 60 (45-77) .395
Sex .326
Male 18 (50%) 9 (42.8%) 9 (60%)
Female 18 (50%) 12 (57.2%) 6 (40%)
Clinical stage .663
I 3 (8.3%) 2 (9.5%) 1 (7%)
II 20 (55.7%) 12 (57.2%) 8 (53%)
III 13 (36.0%) 7 (33.3%) 6 (40%)
IV 0 (0%) 0 (0%) 0 (0%)
KPS score, before CRT .0982
80-90 26 (72%) 13 (62%) 13 (86%)
60-70 7 (20%) 6 (29%) 1 (7%)
40-50 3 (8%) 2 (9%) 1 (7%)
N/A 0 (0%) 0 (0%) 0 (0%)
KPS score, after CRT .249
80-90 18 (50%) 8 (38%) 10 (67%)
60-70 11 (31%) 11 (53%) 0 (0%)
50-40 4 (11%) 2 (9%) 2 (13%)
N/A 3 (8%) 0 (0%) 3 (20%)
Treatment -
Chemo 5-flurouracil 36 (100%) 21 (100%) 15 (100%)
Chemo mitomycin-C 36 (100%) 21 (100%) 15 (100%)
RT Dose mean (std) 54.8  2.9 Gy 55.8  2.1 Gy 53.5  3.4 Gy
Abbreviations: CRT Z chemoradiation therapy; KPS Z Karnofsky performance status; N/A Z not available; RT Z radiation therapy.
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negative slope through the course of treatment and re-
covery in all cases 2 weeks after CRT. The exception was
PLT counts, which recovered shortly after the week 3
nadir during treatment. Average WBC count significantly
decreased from pre-CRT (7.8  2.4 k/mL) to week 4
(4.5  1.9 k/mL) and then remained low through weeks 5,
6, and 7. WBC counts after treatment increased (5.1  1.5
k/mL). A similar trend was observed in ANC, LC, and Hg
levels.
Predictors of hematologic toxicity
We further examined the correlation between HT and
image-defined variables (SUVmean, ABM) and dosimetric
parameters. Acute and post-CRT HT in relation to PET-
defined variables and dosimetric parameters areFigure 2 Pelvic metabolic uptakes (SUVmean) comparison between
pelvis: the lumbosacral region (P < .001); and (c) LP-pelvis: ilium arepresented in Table 2. WBC, ANC, LC, and Hg signif-
icantly correlated with multiple variables (indicated in
Table 2). No significant correlations were found for PLT.
The parameters most significantly correlated with DWBC
and DANC were DSUVmean and DABM for LSBM. In
terms of subregional HT, the LS pelvic region had more
significant associations (eg, DSUVmean and DABM) than
the LP pelvic region. To better interpret the relationship
between HT and clinical imaging and dosimetric vari-
ables, we performed linear regression modeling for ABM
and HT, as well as radiation dose distribution and HT.
Correlation between active bone marrow and hemato-
logic toxicity
The graphs in Figure 3 are linear regression models
that were fit to correlate the DABM within LSBM with
DWBC and DANC. The DWBC was linearly correlatedpre- and post-CRT PET. (a) whole pelvis (P Z .0003); (b) LS-
nd lower pelvis region (P Z .011).
Table 2 Correlation between CRT-induced hematologic toxicity measurements and subregional pelvic and dosimetric parameters












SUVmean, before 0.143 0.261 0.213 0.437 0.556 0.250 0.048 0.647 0.019* 0.892
SUVmean, after 0.055 0.248 0.041* 0.143 0.462 0.482 0.237 0.683 0.123 0.653
D SUVmean 0.980 0.220 0.986 0.033* 0.586 0.837 0.693 0.355 0.716 0.179
ABM before 0.252 0.226 0.105 0.477 0.320 0.162 0.094 0.996 0.059 0.698
ABM after 0.078 0.201 0.038* 0.152 0.338 0.447 0.273 0.559 0.115 0.884
D ABM 0.463 0.259 0.590 0.043* 0.862 0.935 0.944 0.315 0.486 0.355
LSBM
SUVmean, before 0.099 0.786 0.935 0.744 0.504 0.382 0.225 0.630 0.036* 0.446
SUVmean, after 0.147 0.183 0.043* 0.210 0.626 0.389 0.352 0.472 0.117 0.887
D SUVmean 0.521 0.002* 0.199 0.015* 0.427 0.453 0.975 0.322 0.825 0.914
ABM before 0.255 0.406 0.123 0.649 0.580 0.183 0.051 0.714 0.025* 0.957
ABM after 0.283 0.124 0.065 0.214 0.398 0.344 0.347 0.404 0.158 0.832
D ABM 0.758 0.033* 0.388 0.029* 0.743 0.576 0.870 0.085 0.390 0.790
LPBM
SUVmean, before 0.125 0.488 0.743 0.332 0.846 0.226 0.100 0.632 0.032* 0.559
SUVmean, after 0.049* 0.303 0.054* 0.148 0.383 0.563 0.203 0.811 0.136 0.617
D SUVmean 0.847 0.057* 0.336 0.051* 0.505 0.995 0.880 0.509 0.619 0.542
ABM before 0.286 0.176 0.217 0.415 0.398 0.170 0.119 0.818 0.094 0.601
ABM after 0.053* 0.270 0.044* 0.142 0.299 0.548 0.251 0.662 0.114 0.827
D ABM 0.369 0.452 0.474 0.062 0.997 0.888 0.926 0.611 0.436 0.269
Dose
Mean dose 0.464 0.720 0.430 0.427 0.323 0.393 0.391 0.260 0.073 0.722
TBM V10 Gy 0.560 0.945 0.396 0.922 0.490 0.981 0.778 0.344 0.562 0.167
TBM V20 Gy 0.928 0.838 0.309 0.483 0.249 0.562 0.756 0.256 0.890 0.189
TBM V30 Gy 0.295 0.372 0.177 0.394 0.542 0.321 0.681 0.607 0.324 0.766
TBM V40 Gy 0.058 0.262 0.235 0.330 0.843 0.807 0.759 0.196 0.321 0.094
TBM V50 Gy 0.073 0.605 0.027* 0.438 0.033* 0.422 0.448 0.893 0.747 0.468
ABM V10 Gy 0.992 0.430 0.864 0.368 0.656 0.315 0.649 0.102 0.335 0.064
ABM V20 Gy 0.411 0.686 0.665 0.521 0.967 0.390 0.901 0.125 0.625 0.116
ABM V30 Gy 0.907 0.752 0.932 0.828 0.982 1.000 0.913 0.895 0.363 0.509
ABM V40 Gy 0.014* 0.904 0.077 0.934 0.529 0.922 0.783 0.416 0.370 0.070
ABM V50 Gy 0.021* 0.088 0.028* 0.102 0.100 0.206 0.134 0.294 0.226 0.388
Abbreviations: ABM Z active bone marrow; ANC Z absolute neutrophil count; CRT Z chemoradiation therapy; Hgb Z hemoglobin;
LSBM Z lumbosacral bone marrow; LPBM Z lower pelvis bone marrow; SUV Z standard uptake value; TBM Z total bone marrow;
WBC Z white blood cell count.
* P  .05.
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95% confidence interval, 0.22-4.894; Table E1 , available
online at https://doi.org/10.1016/j.adro.2019.06.005).
Similarly, we found that the DANC linearly correlated
with LSBM DABM (P Z .029; b Z 2.041; R2 Z 0.2;
95% confidence interval, 0.234-3.847).
Correlation between radiation dose and hematologic
toxicity
TBM and ABM within increasing dosimetric sub-
regions (ie, V10 Gy, V20 Gy, V30 Gy, V40 Gy, and
V50 Gy) were correlated with HT (Table 2). The pre-CRT
ABM and TBM were used for dose-volume histograms.
The V50 Gy of ABM was significantly associated withacute HT for DWBC (PZ .021) and DANC (PZ .028).
The V50 of TBM was significantly associated with acute
HT for DANC (P Z .027) and DLC (P Z .033). These
results, in conjunction with the RTOG 0529 bone marrow
constraints, resulted in a linear regression analysis of
ABM V40 Gy (Fig 4). A negative linear regression can be
observed for DWBC and DANC related to ABM V40 Gy.
With linear regression, the DWBC can be modeled as a
function of ABM V40, expressed as
DWBC Z e0.052  V40 to 1.53, with P Z .014 and
standard error of the fit Sy.x Z 1.967. The HL test was
used to test the goodness of fit, with P Z .0122.
Similarly, DANC can be fitted as a linear function of
ABM V40 Gy, expressed as DANC Z -0.039  V40 to
Figure 3 Hematologic toxicity as a function of changes of lumbosacral pelvic active bone marrow. (a) Post-chemoradiation therapy
change in white blood cell count is linearly correlated to lumbosacral pelvic change in active bone marrow (P Z .033); and (b) post-
chemoradiation therapy change in absolute neutrophil count as a function of lumbosacral pelvic change in active bone marrow
(P Z .029)
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Sy.xZ 1.618. The goodness of fit of the HL test achieves
a P Z .077.
We further identified the threshold of ABM V40 cor-
responding to the median post-CRT HT in our data.
Relying on the linear regression function derived as
described, the median value of DWBC e2.79 corre-
sponded to ABM V40 Z 24.2%, whereas the median
value of DANC (-1.31) indicated ABM V40Z 20%. Our
results suggest that ABM V40 Gy  20% to 25% cor-
relates to low post-CRT HT. We used multivariable linear
regression to identify the correlation between dose ABM
V40 and 2 HT variables (DWBC and DANC). The results
of the regression show that the area under the curve of the
receiver operating characteristic analysis is 0.625 for
V40 > 20%, 0.571 for V40 > 25%, and 0.569 for
V40 > 18%. For V40 > 20%, the sensitivity of the
classification is 0.565, specificity is 0.692, positive pre-
dictive value is 0.764, and negative predictive value is
0.474 (true positive Z 13; false negative Z 10; false
positiveZ 4; and true negativeZ 9). The performance of
the classification is also interpreted by the Matthews
correlation coefficient of 0.248. We determined 2 variableFigure 4 Hematologic toxicity as a function of V40 of active bone m
regression with post-chemoradiation therapy. (a) Change in white blo
count (P Z .077).correlations (DWBC and DANC) to have a Pearson co-
efficient of 0.877 and a multicollinearities index variance
inflation factor of 4.334, which is less than the ad hoc data
range of 5 to 10.Discussion
These results build on a growing body of literature
suggesting PET imaging is an effective approach for
evaluating changes in ABM due to CRT and the impact
on HT in patients with anal cancer. Our technique for
identifying areas of ABM was similar to that of Notice-
wala et al,12 such that irradiated pelvic regions were
normalized to unirradiated extrapelvic bone marrow. We
used both pre- and posttreatment PET images and iden-
tified significant changes in mean SUV and ABM as a
function of CRT. This approach was similar to the one
used by Lee et al16 and Freese et al,17 but our novelty of
using both pre- and post-PET images allowed for identi-
fication of changes in the ABM regions. Specifically, the
lumbosacral DABM was the area of the strongest corre-
lation. Next, we derived a novel formula for estimatingarrow. V40 Gy of change in active bone marrow negative linear
od cell count (P Z .014); and (b) change in absolute neutrophil
620 J.M. David et al Advances in Radiation Oncology: OctobereDecember 2019the DWBC and DANC by using a V40 Gy dose distri-
bution. Lastly, to our knowledge, this is the first study to
suggest that patients whose ABM V40 Gy  20% to 25%
had a significant reduction in HT, which correlated with
pre- and post-PET scans.
Our study suggests that changes in pelvic ABM during
CRT, as identified using PET/CT scans, correlates well
with HT, including neutropenia, lymphopenia, and
thrombocytopenia. The significance of these findings
seems to be greater for lumbro-sacral bone marrow
compared with lower pelvic bone marrow ABM. In
addition, the analysis of bone marrow dosimetric param-
eters suggests that the severity of HT linearly correlates
with increasing dose to ABM. The slope of the linear fit
can be used to estimate changes in WBC counts. For
example, to avoid DWBC 1, our results suggest that
V40 Gy of ABM should be <20%. Meanwhile, to ach-
ieve DANC 1, ABM V40 Gy should be <25%.
Several reports suggest that low-dose irradiated pelvic
bone marrow is associated with leukopenia and other
HTs. Mell et al18 reported that low-dose irradiation of
whole pelvic bone marrow PBM-V10 was associated with
HT, and patients with PBM-V10  90% were more likely
to develop HT. Rose et al also recommended PBM-
V10 < 95% and V20 < 80% to reduce grade 3 (G3)
leukopenia risk. Additional reports have indicated that
high doses of specific subregional pelvic bone marrow are
more important in the development of HT. For example,
Franco et al showed that LSBM mean dose is significantly
correlated with G3 leukopenia and suggested an LSBM
mean dose <32 Gy to minimize G3 HT in patients with
anal cancer.19 Another study of the same group suggested
that patients with LSBM-V40 > 41% were more likely to
develop  G3 HT.20 Lee et al reported that acute G3
neutropenia and leukopenia may be limited by con-
straining the lower pelvic bone marrow to V40 Gy  25%
and a V20 Gy  90%. The latter results are in line with
our findings of LS-ABM-V40  25% based on PET and
CT-based bone marrow contours.
In our patient cohort, the lumbro-sacral bone marrow
most significantly correlated with posttreatment DANC
(PZ .029) and DWBC (PZ .033). Furthermore, areas of
ABM were significantly sensitive to high radiation dose.
Although the volume of ABM receiving 50 Gy was
relatively small (3.2%  4.5% for TBM and
2.8%  5.3% for ABM), THE V50 Gy of ABM was
significantly associated with the acute HT variables
DANC (PZ .027 for TBM and PZ .028 for ABM) and
DWBC (P Z .073 for TBM and P Z .021 for ABM).
Therefore, our results suggest that changes in ABM pre-
dict leukopenia, which can be alleviated or avoided using
the appropriate constraints.
Patients with ABM toxicity leading to increased HT
have more treatment breaks.21 The absence of hospitali-
zations and treatment breaks during CRT for anal cancer
results in significantly improved clinical outcomes.5IMRT has been instrumental in reducing HT and simul-
taneously allows for dose escalation,5,22 which has been
shown to improve colostomy-free survival4,6,23 and
overall survival.5 However, guidelines on proper dose
constraints and identification of active areas in the pelvic
bones have not used PET/CT. Although studies have used
constraints similar to those used in RTOG 0529,3 such as
TBM V50 Gy < 5%, V40 Gy < 35%, and
V30 Gy < 50%, we believe that PET/CT allows more
accurate identification of changes in ABM and develop-
ment of more clinically relevant bone marrow dose con-
straints. The use of PET/CT is feasible for centers with a
PET/CT scanner because it is typically incorporated into
the standard workup of anal cancer patients. Our results
suggest that a constraint on ABM of V40 Gy  20% to
25% may reduce HT, which can lead to a reduction in
treatment breaks and thereby improve clinical outcomes.
The reduction in ABM dose should be incorporated
with known pelvic dose parameters. For example, Lee
et al have shown that reducing the whole pelvis BM
volume to <750 cm3 yielded no G3 leukopenia.16
Additionally, a V40 dose constraint for CT-based lower
pelvis correlated with reduced G3 leukopenia. These
constraints can be achieved with lower prophylactic pel-
vic doses24 for node-negative patients or for omission of
inguinal nodal irradiation in select patients.25,26 Despite
compelling evidence in small, single-institution, retro-
spective studies suggesting omission of elective inguinal
nodal irradiation, the risk of clinically detected regional
nodal involvement was 29% for all patients in a Sur-
veillance, Epidemiology, and End Results data analysis,27
and T/N stage was shown to be strongly prognostic of
disease-free survival, overall survival, and colostomy
failure in RTOG 98-11.4 Additionally, Ortholan et al
showed inguinal recurrence rates of 12% and 30% in
patients with cT1/2 and cT3/4 tumors, respectively, when
elective inguinal nodal irradiation was omitted and
inguinal failure rates of only 2% when it was included.28
Based on these and similar data, the National Compre-
hensive Cancer Network recommends inclusion of
inguinal nodal basins for all patients with nonmetastatic
anal carcinoma treated with definitive chemoradiation.2
Perhaps the most significant contributor to HT is
chemotherapy. Several experimental chemotherapy regi-
mens have been prospectively compared with the current
standard of 5-FU/MMC. In the ACT II trial, cisplatin with
5-FU resulted in improved grade 3/4 HT compared with
5-FU/MMC but yielded no difference in neutropenic
sepsis or survival.8 Capecitabine has also been investi-
gated in large retrospective studies as an alternative to
infusional 5-FU. Goodman et al identified a significant
reduction of grade 3 HT and treatment interruptions of
32% and 26%, respectively, with equivalent clinical
outcomes, and suggested capecitabine as a suitable
alternative to 5-FU.29 In cases where dose constraints are
not achievable, some consider following a European
Advances in Radiation Oncology: OctobereDecember 2019 PET predicts hematologic toxicity 621approach using single-dose MMC in select patients,
which likely has a greater effect on HT than RT.30,31
Additional studies will be required to assess the com-
bined impact of varying pelvic radiation dose, elective
treatment of inguinal nodes, and type of chemotherapy on
both clinical outcomes and HT.
We recognize there are limitations to our study. This
study is retrospective, with a limited number of patients.
Therefore, it may lack generalizability. Furthermore,
data were collected from 2 institutions, so there may be
differences in PET/CT scanners and protocols, which
may create minor differences in SUVmax.
32 However,
intrapatient normalization of SUVmax to background
extrapelvic bone uptake likely mitigated this issue.12
There may also be differences in the laboratory anal-
ysis of blood samples between the institutions, although
ie, unlikely to affect the delta for each individual patient
throughout treatment. The threshold V40 Gy  20% to
25% is derived from the limited number of patients and
may introduce uncertainty due to the fitting of the model.
The timing of post-CRT PET had a range of 6 to
16 weeks, but there was only a 2-week interquartile
range around a median of 12 weeks; there is possibility
for variations in PET SUV values. Lastly, the effect of
chemotherapy may vary between patients because 5-FU
and MMC have a range for standard doses, which may
be different for each patient. However, again one would
expect that the differences in systemic effect would be
mitigated when normalizing background extrapelvic
bone uptake.Conclusions
Our results are consistent with and build upon a
growing body of literature indicating that ABM can be
correlated with hematologic values. The use of pre- and
post-18F-PET/CT scans provides a robust approach to
the delineation of the ABM. Determination of changes
in ABM between pre- and post-CRT PET is signifi-
cantly associated with HT in patients with anal cancer
undergoing CRT. LSBM ABM has the strongest cor-
relation with HT, and a constraint on V40 Gy for ABM
<20% to 25% can be used to minimize HT. Ultimately,
avoidance of PET-based ABM may significantly reduce
the risk of HT and can lead to decreased treatment
delays, which are associated with superior clinical
outcomes.Supplementary data
Supplementary material for this article can be found at
https://doi.org/10.1016/j.adro.2019.06.005.References
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